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ABSTRACT 
Background: The majority of clinical trials investigating the clinical benefits 
of lipid-lowering therapies (LLTs) have focused on North American or western 
and nothern European populations. Therefore, it is timely to confirm the effi- 
cacy of these agents in other patient populations in routine clinical practice. 
Objective: The aim of the Direct Statin COmparison of low-density lipopro- 
rein cholesterol (LDL-C) Values: an Evaluation of Rosuvastatin therapY 
(DISCOVERY) Alpha study was to compare the effects of rosuvastatin 10 mg 
with those of atorvastatin 10 mg in achieving LDL-C goals in the Third Joint Task 
Force of European and Other Societies on Cardiovascular Disease Prevention in 
Clinical Practice guidelines. 
Methods: This randomized, open-label, parallel-group study was conducted 
at 93 centers in eastern Europe (Estonia, Latvia, Romania, Russia, Slovenia), 
Central and South America (Chile, Dominican Republic, E1 Salvador, Guatemala, 
Honduras, Nicaragua, Panama), and the Middle East (Israel, Kuwait, Saudi 
Arabia, United Arab Emirates). Male and female patients aged ~18 years with pri- 
mary hypercholesterolemia (LDL-C level, >135 mg/dL if LLT-naive or ~120 mg/dL 
if switching statins; triglyceride [TG] level, <400 mg/dL) and a 10-year coronary 
heart disease (CHD) risk >20% or a history of CHD or other established athero- 
sclerotic disease were eligible for inclusion in the study. Patients were randomly 
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assigned to receive rosuvastatin 10-mg or atorvastatin 10-mg tablets QD for 
12 weeks. No formal statistical analyses or comparisons were performed on 
lipid changes between switched and LLT-naive patients because of the different 
lipid inclusion criteria for these patients. The primary end point was the pro- 
portion of patients achieving 1998 European LDL-C goals after 12 weeks of treat- 
ment. A subanalysis was performed to assess the effects of statins in patients 
who had received previous tatin treatment versus those who were LLT-naive. 
Tolerability was assessed using laboratory analysis and direct questioning of 
the patients. 
Results: A total of 1506 patients (52.1% women, 47.9% men; mean [SD] age, 
58.2 [10.8] years) participated in the study (rosuvastatin, 1002 patients; ator- 
vastatin, 504 patients; previous LLT, 567 patients). A significantly higher propor- 
tion of patients achieved 1998 European LDL-C goals after 12 weeks with rosuva- 
statin 10 mg than with atorvastatin 10 mg (72.5% vs 56.6%; P < 0.001). Similarly, 
more patients achieved the 2003 European LDL-C goals with rosuvastatin 10 mg 
compared with atorvastatin 10 mg (57.5% vs 39.2%). Rosuvastatin 10 mg was 
associated with a significantly greater change in LDL-C levels compared with 
atorvastatin 10 mg, in patients who were LLT-naive (LDL-C: --44.7% vs -33.9%; 
P (0.001) and in patients who had received previous LLT (LDL-C: -32.0% vs 
-26.5%; P = 0.006). TG levels were also decreased with rosuvastatin 10 mg and 
atorvastatin 10 mg, although there was no significant difference between treat- 
ments. Similarly, there was no significant difference in the increase in high- 
density lipoprotein cholesterol levels between treatments. The most common 
adverse vents overall were headache 16/1497 (1.1%), myalgia 10/1497 (0.7 %), 
and nausea 10/1497 (0.7%). 
Conclusions: In this study in patients with primary hypercholesterolemia in 
clinical practice, greater eductions in LDL-C levels were achieved with a start- 
ing dose (10 mg) of rosuvastatin compared with atorvastatin 10 mg, with more 
patients achieving European LDL-C goals. Both treatments were well tolerated. 
(Curr Ther Res CI& Exp. 2006;67:21-43) Copyright © 2006 Excerpta Medica, Inc. 
Key words: hypercholesterolemia, st tin, low-density lipoprotein cholesterol, 
rosuvastatin, atorvastatin. 
INTRODUCTION 
Coronary heart disease (CHD) is a major cause of death worldwide. 1,2 In most 
developing countries, the incidence of cardiovascular disease (CVD) is increas- 
ing toward epidemic proportions. 3 In some regions, such as eastern Europe, 
CVD accounts for almost 50% of all deaths. 4 CHD mortality rates are particularly 
high in eastern Europe, with age-adjusted mortality rates for men aged 35 to 
74 years ranging from 211 to 839 deaths per 100,000 population compared with 
83 to 210 deaths per 100,000 population in southern and central Europe. 4The 
burden of CVD in Latin America is also high. In Chile, CVD accounts for 28% of all 
deaths. 5 The burden of CVD in the Middle East is also high and the age-adjusted 
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CHD event rates in Jerusalem are similar to those observed in northern and 
eastern Europe. 6The risk factors for CVD must be addressed if the burden of 
these diseases is to be minimized. 
Elevated serum levels of low-density lipoprotein cholesterol (LDL-C) and 
total cholesterol (TC) have been established as major risk factors for CHD. 
The Interheart study, 7a standardized, case-control study of acute myocardial 
infarctions in 52 countries, reported that abnormal serum lipid levels were 1 of 
the 2 most important modifiable risk factors contributing to cardiovascular 
events worldwide. The importance of elevated LDL-C and TC is reflected in 
the National Cholesterol Education Program Adult Treatment Panel III (ATP III) 8 
and Third Joint Task Force of European and Other Societies on CVD 
Prevention in Clinical Practice guidelines 9 for the prevention of CHD, which 
recommend that elevated lipid levels be reduced. A target LDL-C of <70 mg/dL 
(<1.8 mmol/L) is recommended in ATP III for patients at very high risk for CHD 
events. 1° Lowering LDL-C to the recommended level has been associated with 
a reduction in the number of cardiovascular events. 11A2 The Treating to New 
Targets (TNT) study, 13 a multinational trial in 10,001 patients with clinically 
evident CHD, found that reducing the LDL-C level to substantially less (77 mg/dL 
[2 mmol/L]) than the ATP III goal of 100 mg/dL (¢2.5 mmol/L) can decrease the 
risk (risk reduction, 22% relative to a mean LDL-C of 101 mg/dL [2.5 mmol/L]) 
for cardiovascular events in patients with CHD. 
Liao 14 has suggested that only some of the benefit of hydroxymethylglutaryl 
coenzyme A reductase inhibitors ("statins") in reducing cardiovascular risk 
is derived from their ability to lower LDL-C levels. Lipid-independent or
pleiotropic effects (eg, the ability to modify inflammation, endothelial func- 
tion, and revascularization) have been reported with the use of various 
statins. 14 Because these effects occur in parallel with changes in lipid levels, 
which reduce the frequency of CHD events, it is difficult to separate and 
assess the direct clinical relevance of these pleiotropic effects. The clinical 
relevance of such pleiotropic effects has not yet been identified in specific 
prospective outcomes tudies. 15 Furthermore, an analysis of outcomes trials 
that adjusted for lipid changes uggested that the degree of lipid lowering, 
rather than a specific lipid-lowering therapy (LLT), accounts for the reduction 
in CHD events. 15 That analysis, combined with data from the TNT study, 13 sup- 
ports the suggestion that lower LDL-C levels are better and highlights the 
importance of attaining lipid goals in reducing the risk for cardiovascular 
events. 13 
Despite the increasing use of LLTs, many patients fail to achieve lipid goals 
recommended in the current guidelines. 16Although the effectiveness of LLTs 
increases with dose, doses are rarely titrated. 17,18 Increasing physicians' aware- 
ness concerning the guidelines and the importance of reaching LDL-C goals 
might help to improve lipid management, as might educating patients concern- 
ing ways to improve compliance with therapy. The availability of more effective 
LLTs also helps to improve lipid management. 
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Rosuvastatin has been shown to be highly efficacious in modifying lipid lev- 
els and, at an initial close of 10 mg, has been associated with a greater eduction 
in LDL-C levels compared with other statins at their respective starting doses 
and on a milligram-equivalent basis. 19-21 Results from large-scale trials investi- 
gating the effects of rosuvastatin on cardiovascular outcomes are currently 
unavailable, although such studies are ongoing. 22 
Hypercholesterolemia is public health problem that contributes to CHD in 
most developing countries. 7,23 However, the majority of clinical trials investigat- 
ing the clinical benefits and lipid-lowering efficacy of LLTs have focused on North 
American or western and northern European populations. Therefore, it is timely 
to confirm the efficacy of these agents in routine clinical practice and in previously 
underrepresented patient populations. 
The Direct Statin COmparison of LDL-C Values: an Evaluation of Rosuvastatin 
therapy (DISCOVERY) study was a series of 9 independently powered studies 
performed in different countries and regions worldwide, including: (1) The 
Netherlands; (2) Triple Country (Iceland, Ireland, Finland); (3) Asia; (4) Alpha 
(eastern Europe, Central and South America, the Middle East); (5) Belux (Bel- 
gium, Luxembourg); (6) Canada; (7) Penta (Latin America, Portugal); (8) Beta (Es- 
tonia); and (9) the United Kingdom. These studies aimed to compare the effi- 
cacy of rosuvastatin 10 mg with that of other statins (given at their respective 
recommended starting doses) in achieving recommended lipid levels in the 
clinical setting. To date, >11,000 patients have been enrolled in the DISCOVERY 
study program, which started in March 2002. 
The aim of this report is to provide the results of 1 DISCOVERY study, 
DISCOVERY Alpha, which compared the efficacy of rosuvastatin 10 mg with that 
of atorvastatin 10 mg. 
PATIENTS AND METHODS 
Study Design 
DISCOVERY Alpha was an open-label, randomized, parallel-group study con- 
ducted at 93 centers in eastern Europe (Estonia, Latvia, Romania, Russia, 
Slovenia), Central and South America (Chile, Dominican Republic, E1 Salvador, 
Guatemala, Honduras, Nicaragua, Panama), and the Middle East (Israel, Kuwait, 
Saudi Arabia, United Arab Emirates). The study was performed in accordance 
with the ethical principles of the Declaration of Helsinki and its amendments 26 
and was consistent with International Conference on Harmonization/Good 
Clinical Practice and applicable regulatory requirements. 27 The study protocol 
and informed-consent form were approved in writing by the independent ethics 
committee at each center. 
Inclusion and Exclusion Criteria 
Male and female patients aged >18 years with primary hypercholesterolemia 
(LDL-C >3.5 mmol/L [135 mg/dL] if LLT-naive [ie, no LLT in the previous 6months] 
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or _>3.1 mmol/L [120 mg/dL] if switching; and triglycerides [TG] <4.52 mmol/L 
[400 mg/dL]) and a 10-year CHD risk >20%, as defined by the 1998 European 
guidelines, 28or a history of CHD or other established atherosclerotic disease 
were eligible for inclusion in the study. 
Exclusion criteria were as follows: familial hypercholesterolemia or dysbeta- 
lipoproteinemia; secondary dyslipidemia of any cause; a history of hypersen- 
sitivity to statins; uncontrolled iabetes mellitus (DM) or hypertension; 
unstable CVD (including unstable angina); active hepatic disease or hepatic 
dysfunction (alanine aminotransferase and aspartate aminotransferase level 
_>l.5-fold the upper limit of normal [x ULN]); unexplained serum creatine 
kinase (CK) >3 x ULN; women of childbearing age not using contraception, 
or who were pregnant or breastfeeding; and current reatment with medica- 
tions not allowed during the study (lipid-modifying agents [eg, fibrates, 
niacin/nicotinic acid, bile acid sequestrants, other statins, probucol, fish 
oils, lipid-modifying dietary supplements, food additives] or agents known to 
interact with statins and increase the risk for muscular adverse vents [AEs] 
[eg, cyclosporine, clarithromycin, erythromycin, fluconazole, ketoconazole, 
itraconazole]). 
The principal investigator ateach center ensured that each patient was given 
full, adequate oral and written information about the nature, purpose, and 
possible risks and benefits of the study. Written informed consent was obtained 
from each patient. 
Study Drug Administration 
Patients were assessed for eligibility and, within 2 weeks, were randomized 
in a 2:1 ratio to receive rosuvastatin 10 mg or atorvastatin 10 mg administered 
QD by mouth (tablets) for 12 weeks. These doses were chosen because they 
were the initial doses recommended in the product information when the study 
was conducted. 29,3° 
Randomization was performed as follows. Patients were allocated num- 
bers as they entered the study, and a computer-generated randomization 
scheme was used to determine treatment allocation as patients became li- 
gible. Treatment codes for each patient were provided to each center in a 
sealed envelope, and investigators and study monitors were unaware of the 
randomization scheme and treatment codes until the envelope was opened 
at the randomization visit. 
Patients who were LLT-naive underwent dietary counseling 6 weeks before 
the study, whereas patients already receiving a commonly used or initial dose 
of an LLT who had not reached their 1998 European LDL-C goal were switched 
to a study medication without a run-in period. 
Efficacy and Tolerability Assessments 
At each visit (screening [week -2], randomization [week 0], and final visit 
[week 12]), blood samples were drawn to determine serum levels of TC, high- 
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density lipoprotein cholesterol (HDL-C), and TG. Serum LDL-C level was deter- 
mined using the Friedewald formula. 31 
The primary end point was the percentage of patients achieving 1998 Joint 
European LDL-C goals (<115 mg/dL [<3.0 mmol/L]) 28 at week 12. Secondary effi- 
cacy end points included the percentage of patients achieving the 1998 Joint 
European TC goal 28 (<190 mg/dL [<5.0 mmol/L]) and the percentage change from 
baseline in serum LDL-C, TC, HDL-C, and TG levels in LLT-naive and switched 
patients. 
During the course of the study, the new (2003) Joint European guideline for 
CVD prevention 9 became available, and a post hoc data analysis was conducted 
according to these new guidelines and the prespecified 1998 European lipid goals. 
The 2003 European guidelines have more stringent lipid goals (LDL-C <100 mg/dL 
[<2.5 mmol/L]; TC <175 mg/dL [<4.5 mmol/L]) in patients who have established 
atherosclerotic disease or DM or who are at high risk for cardiovascular events 
(ie, assessed as having a Systematic Coronary Risk Evaluation risk _>5%). 9 
Lipid goals remained at LDL-C <115 mg/dL (<3.0 mmol/L) and TC <190 mg/dL 
(<5.0 mmol/L) in patients at low risk. 9 Lipid levels were determined from fasting 
(12 hours) blood samples analyzed at local laboratories. 
Because procedures and calculation methods may have differed between lo- 
cal laboratories, all reported LDL-C levels were recalculated using the Friedewald 
formula 31 for consistency, as specified in the protocol. Although this recalcula- 
tion could result in the inclusion of ineligible patients based on locally deter- 
mined LDL-C levels (this occurred in 4.8% of patients in the rosuvastatin 10-mg 
group and 5.6% in the atorvastatin 10-mg group), it was not anticipated that 
the percentage change in LDL-C would vary according to the method used. 
Therefore, those individuals were included in the intent-to-treat (ITT) pop- 
ulation used for the efficacy analyses. Because patients with TG _>400 mg/dL 
(~4.52 mmol/L) were excluded from the study, the confounding effect of ele- 
vated TG level on the Friedewald formula 31 was minimized. 
Compliance with treatment was determined using a count of unused tablets 
returned at the last study visit. 
The incidence and severity of AEs, including abnormal laboratory values 
(liver enzymes, creatinine, and CK), were recorded to assess tolerability. AEs 
were reported to investigators in response to a standard question ("How have 
you felt since the last study visit?") that each patient was asked at each visit. 
Also, any decline in a patient's condition subsequent tostudy entry was consid- 
ered an AE. Investigators assessed the seriousness ofeach AE, and if an AE was 
considered serious, its relationship to treatment was assessed. 
Statistical Analysis 
To enable detection of a difference of 5% between the percentage of pa- 
tients achieving the 1998 European LDL-C goal with rosuvastatin 10 mg or 
atorvastatin 10 mg with 90% power for a 2-sided significance level of 5%, it 
was estimated that 1365 patients would need to be enrolled if using a ran- 
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domization ratio of 2:1. Allowing for a 10% withdrawal rate during the study, 
we planned to enroll 1517 patients. 
Efficacy analyses were performed on the ITT population, which comprised 
all patients who had baseline and week-12 lipid levels available and had 
received at least 1 dose of study medication. The proportions of patients 
attaining the various lipid goals with rosuvastatin and atorvastatin were 
compared using a logistic regression analysis, with factors fitted for treat- 
ment, country, subject type (LLT-naive or switched), and treatment-by-  
subject-type interaction, and with the baseline lipid value fitted as a covari- 
ate. A significant reatment-by-patient-type int raction (P < 0.05) indicated 
different treatment effects in LLT-naive and switched patients. Thus, the 
nature of the interaction (ie, quantitative or qualitative) was investigated, 
and the treatment comparisons were presented separately for each patient 
type. If the interaction was not significant, the term was dropped from the fi- 
nal model and the results were analyzed and presented for both patient 
types combined. The treatment-by-patient-type int raction was significant 
(P < 0.05) for only the 2003 European LDL-C goal. Therefore, results for LLT-naive 
and switched patients are presented separately for this goal only. The over- 
all results have been presented for completeness but without statistical 
analysis. Because LLT-naive and switched patients had different lipid require- 
ments for inclusion, the percentage changes in lipid levels--reported as least 
squares means (ie, means adjusted for factors fitted in the statistical 
model)- -were analyzed separately for LLT-naive and switched patients, and 
no formal analyses or comparisons were performed between these 2 groups 
of patients. Treatment comparisons were performed using an analysis of 
covariance, with factors fitted for treatment and country. Descriptive tolera- 
bility analyses were conducted on data from all patients who had received at 
least 1 dose of study medication (tolerability data set). 
RESULTS 
Study Population 
The first patient was randomized on May 6, 2003, and the last, on March 10, 
2004. The last patient completed the study on June 17, 2004. A total of 1506 
patients (52.1% women, 47.9% men; mean [SD] age, 58.2 [10.8] years) were 
enrolled in the trial (rosuvastatin, 1002 patients; atorvastatin, 504 patients); 
1497 (rosuvastatin, 998 patients; atorvastatin, 499 patients) received at least 
1 dose of study medication and were included in the tolerability data set. In total, 
1412 individuals received at least 1 dose of the study drug and had baseline and 
week-12 lipid measurements available (ITT data set) (rosuvastatin, 937 patients; 
atorvastatin, 475 patients). A total of 78 (7.8%) patients in the rosuvastatin group 
and 36 (7.1%) patients in the atorvastatin group were withdrawn from the study 
(Figure 1). Reasons for discontinuation i cluded noncompliance with the study 
protocol (rosuvastatin, 46 [4.6%] patients; atorvastatin, 19 [3.8%] patients), with- 
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Figure 1. Study des ign.  AEs = adverse events.  
Discontinued (n = 246) 
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fulfilled (n = 219) 
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consent (n = 16) 
Lost to follow-up (n = 6) 
Other (n = 5) 
Discontinued (n = 36) 
Noncompliance with 
protocol (n = 19) 
Withdrawal of informed 
consent (n = 2) 
AEs (n = 14) 
Other (n = 1) 
drawal of consent (rosuvastatin, 9 [0.9%], atorvastatin, 2 [0.4%]), AEs (rosuva- 
statin, 23 [2.3%]; atorvastatin, 14 [2.8%]), and other (unspecified) reasons (ator- 
vastatin, 1 [0.2%]). 
Baseline demographic and clinical characteristics were similar between the 
2 treatment groups (Table I). The incidence of risk factors (ie, type 2 DM, doc- 
umented atherosclerotic disease, family history of premature CHD or periph- 
eral vascular disease, hypertension, low HDL-C level, or elevated TG level), was 
numerically similar between the 2 treatment groups. In total, 651 (43.5%) pa- 
tients had documented atherosclerotic disease, 527 (35.2%) had type 2 DM, 
411 (27.5%) had a family history of premature CHD or peripheral vascular dis- 
ease, and 382 (25.5%) were smokers. In the rosuvastatin group, 382 (40.8%) had 
previously received LLT compared with 185 (38.9%) in the atorvastatin group. 
The most frequently prescribed LLTs were simvastatin 20 mg (226 [39.9%]), 
simvastatin 10 mg (138 [24.3%]), atorvastatin 10 mg (97 [17.1%]), and prava- 
statin 20 mg (62 [10.9%]). 
Data concerning treatment compliance were poorly recorded throughout the 
study, with patients losing medication or failing to return it for counting. 
Nonetheless, mean compliance was numerically similar between the 2 treatment 
groups (rosuvastatin, 101.1%; atorvastatin, 100.8%). 
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Table I. Baseline demographic and clinical characteristics of the study patients.* 
Rosuvastatin Atorvastatin 
Characteristic (n = 1002) (n = 504) 
Age, t mean (SD), y 58.4 (10.9) 58.0 (10.5) 
Sex, t no. (%) 
Female 495 (52.8) 241 (50.7) 
Male 442 (47.2) 234 (49.3) 
Race, t % 
White 817 (87.2) 401 (84.4) 
Black 11 (1.2) 6 (1.3) 
Oriental 8 (0.9) 9 (1.9) 
Other ~ 101 (10.8) 59 (12.4) 
BMI,§ mean, kg/m 2 28.6 29.0 
Blood pressure, § mean, mm Hg 
Systolic 141.2 140.5 
Diastolic 82.2 82.2 
Risk factors§ 
Atherosclerosis, no. (%) 430 (43.1) 221 (44.3) 
Type 2 DM, no. (%) 348 (34.9) 1 79 (35.9) 
Family history of premature CHD or PVD, no. (%) 275 (27.6) 136 (27.3) 
Smoking habit, no. (%) 253 (25.4) 129 (25.9) 
Low HDL-C, II no. (%) 167 (16.7) 71 (14.2) 
Elevated TG, II no. (%) 416 (41.7) 199 (39.9) 
Previous LLT, t no. (%) 
No 555 (59.2) 290 (61.1) 
Yes 382 (40.8) 185 (38.9) 
Switched from previous LLT, #** no. (%) 
Simvastatin 242 (63.4) 128 (69.2) 
Atorvastatin 71 (18.6) 27 (14.6) 
Pravastatin 50 (I 3.1 ) 19 (I 0.3) 
Lovastatin I0  (2.6) 4 (2.2) 
Fluvastatin 8 (2.1) 6 (3.2) 
Phosphatidyl choline I (0.3) 0 
Gemfibrozil 0 I (0.5) 
BMI = body mass index; DM = diabetes mellitus; CHD = coronary heart disease; PVD = peripheral vascular 
disease; HDL-C = high-density lipoprotein cholesterol; TG = triglycerides; LLT = lipid-lowering therapy. 
*Percentages may not total 100% due to rounding. 
tCaiculated from the intent-to-treat population (rosuvastatin 10 mg, n = 937; atorvastatin 10 mg, n = 475). 
~lncludes patients of Asian, Hispanic, Indian, and mixed race. 
§Calculated from the safety population (rosuvastatin 10 mg, n = 998 [except for BMI, where n = 995]; 
atorvastatin 10 mg, n = 499). 
IILow HDL-C %0.9 mmol/L. 
%levated TG --.2.0 mmol/L. 
#Doses of previous LLT: simvastatin, 5, 10, 20, or 40 mg; atorvastatin, 10 or 60 mg; pravastatin, 10 
or 20 mg; fluvastatin, 10, 20, 40, or 80 mg; Iovastatin, 10 or 20 mg; gemfibrozil, 600 mg; and phos- 
phatidyl choline, 300 mg. 
**Rosuvastatin 10 mg, n = 382; atorvastatin 10 mg, n = 185. 
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Efficacy 
A significantly higher proportion of patients in the rosuvastatin group achieved 
the 1998 European LDL-C goal after 12 weeks compared with the atorvastatin 
group (679 [72.5%] vs 269 [56.6%]; P < 0.001) (Figure 2). In addition, significantly 
more patients achieved the 1998 European TC goal with rosuvastatin compared 
with atorvastatin (611 [65.2%] vs 245 [51.6%]; P < 0.001). 28 A significantly larger 
proportion of LLT-naive and switched patients in the rosuvastatin group achieved 
2003 European LDL-C goals compared with those in the atorvastatin group 
(348/555 [62.7%] vs 114/290 [39.3%] [P < 0.001] and 191/382 [50.0%] vs 72/185 
[38.9%] [P < 0.01], respectively) (F'tg~re 3A). 9 In the total population, a greater pro- 
portion of rosuvastatin-treated patients achieved the 2003 European goals 9 com- 
pared with atorvastatin-treated patients for LDL-C (539 [57.5%] vs 186 [39.2%]) 
(Figure 3A) and TC (495 [52.8%] vs 185 [38.9%]; P < 0.001) (Figure 3B). Because 
there was no statistical difference between switched and LLT-naive patients for 
achieving the 2003 European TC goals, these data were not analyzed separately. 
In LLT-naive patients, the mean (SD) changes from baseline in LDL-C and TC 
levels at 12 weeks were significantly greater with rosuvastatin compared with 
atorvastatin (-44.7% [0.89%] vs-33.9% [1.18%] and-31.9% [0.68%] vs -25.0% 
[0.91%]; both, P < 0.001) (Table II). In patients who had been switched from 
another LLT, mean changes from baseline in LDL-C and TC levels were signifi- 
cantly greater with rosuvastatin compared with atorvastatin (-32.0% [ 1.32%] vs 
-26.5% [1.79%] [P = 0.006] and -22.9% [0.97%] vs -19.7% [1.32%] [P = 0.029], 
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Figure 2. Rates of achievement of 1998 European lipid goals (low-density lipoprotein 
cholesterol [LDL-C] <3.0 mmol/L; total cholesterol [TC] <5.0 mmol/L) in 
patients with hypercholesterolemia receiving treatment with rosuvastatin 
(RSV) 10 mg or atorvastatin (ATV) 10 mg. *P< 0.001 versus ATV. 
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Figure 3. Rates of achievement of 2003 European goals for (A) low-density lipopro- 
tein cholesterol (LDL-C) (<3.0 mmol/L, or <2.5 mmol/L if cardiovascular dis- 
ease [CVD], diabetes mellitus, or high risk for CVD-related death is present) 
and (B) total cholesterol (TC) (<5.0 mmol/L, or <4.5 mmol/L if CVD, diabetes 
mellitus, or high risk for CVD-related death is present) in patients with 
hypercholesterolemia receiving treatment with rosuvastatin (RSV) 10 mg or 
atorvastatin (A'I-V) 10 mg. LLT = lipid-lowering therapy. *P < 0.001 versus 
ATV; tp < 0.01 versus ATV. 
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respectively). In general, the reductions in LDL-C and TC levels were smaller in 
switched patients compared with those in LLT-naive patients. Mean changes in 
TG and HDL-C levels were not significantly different between treatment groups 
in LLT-naive or switched patients. 
Tolerability 
The occurrence of AEs was numerically similar between the 2 treatment 
groups (Tables III and IV). The most common AEs overall were headache (rosu- 
vastatin, 9/998 [0.9%] patients; atorvastatin, 7/499 [1.4%] patients), myalgia 
(6 [0.6%] and 4 [0.8%], respectively), and nausea (6 [0.6%] and 4 [0.8%], respec- 
tively) (Table IV). In none of these cases was myalgia associated with clinically 
significant elevations (>10 X ULN) in CK activity. No patient had clinically signif- 
icant increases in CK, and no case of myopathy (CK >10 x ULN plus muscular 
symptoms) or rhabdomyolysis was recorded. One patient in each treatment 
group was observed to have elevated alanine aminotransferase activity (>3 x 
Table III. Adverse events (AEs) with treatment with rosuvastatin 10 mg or atorva-statin 
10 mg in patients with hypercholesterolemia (tolerability data set).* Data are 
no. (%) of patients. 
Rosuvastatin Atorvastatin 
Category (n = 998) (n = 499) 
Any AE 95 (9.5) 52 (10.4) 
Led to treatment discontinuation 23 (2.3) 14 (2.8) 
Serious t 12 (I .2) 7 (I .4) 
Led to death I (0.1) 2 (0.4) 
*Patients with multiple events in the same category are counted only once in that category. Patients 
with AEs in >1 category are counted once in each category. 
tin 1 patient in each treatment group, the onset of the serious AE reported occurred before the 
commencement of study treatment. 
Table IV. Most common (prevalence, >0.5%) adverse events (AEs) with 
treatment with rosuvastatin 10 mg or atorvastatin 10 mg 
in patients with primary hypercholesterolemia (tolerability 
data set). Data are no. (%) of patients. 
Rosuvastatin Atorvastatin 
AE (n = 998) (n = 499) 
Headache 9 (0.9) 7 (1.4) 
Myalgia 6 (0.6) 4 (0.8) 
Nausea 6 (0.6) 4 (0.8) 
Dizziness 5 (0.5) 4 (0.8) 
Diarrhea 4 (0.4) 4 (0.8) 
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ULN). Mean (SD) serum creatinine l vels were similar between groups at baseline 
(rosuvastatin 10 mg, 78.3 [17.4] iJmol/L; atorvastatin 10 mg, 77.8 [18.6] IJmol/L), 
and changes during the study were small and comparable (rosuvastatin 10 mg, 
-0.4 [14.3] lJmol/L; atorvastatin 10 mg,-0.2 [14.0] pmol/L). The protocol did not 
include a predefined level at which an increase in serum creatinine would 
require notation. However, 1 patient in each group was noted to have an increase 
of -2-fold in serum creatinine level, to -1.5 × ULN. 
The incidence of serious AEs was <1.5%. Cardiovascular AEs were the most 
common nonfatal serious AEs, occurring in 5 (0.5%) patients treated with rosu- 
vastatin (myocardial infarction/ischemia [n = 2], cerebrovascular accident [n = 2], 
and unstable angina [n = 1]) and 6 (1.2%) patients receiving atorvastatin 
(myocardial infarction [n = 2], cerebrovascular accident [n -- 2], and angina pec- 
toris [n = 2]). Only 2 serious AEs were considered by the investigators to be 
treatment related: 1 incidence of abdominal pain and 1 case of hypersensitivity, 
both of which occurred in the rosuvastatin group. AEs led to discontinuation 
of treatment in 23 (2.3%) and 14 (2.8%) patients receiving rosuvastatin and 
atorvastatin, respectively (Table lll). Three deaths occurred uring the study: 
1 (0.1%) patient in the rosuvastatin group (fatal myocardial infarction) and 
2 (0.4%) patients in the atorvastatin group (acute coronary syndrome; ventricular 
fibrillation in a patient with a history of atrial fibrillation, DM, hypertension, and 
myocardial infarction). None of the deaths were considered by the investigator 
to be related to study treatment. 
DISCUSSION 
The results of the DISCOVERY Alpha study suggest hat, at a starting dose of 
10 mg, decreases in LDL-C and TC levels were significantly greater with rosuva- 
statin compared with atorvastatin, and that a significantly greater proportion of 
patients achieved both the 1998 and the more stringent 2003 European LDL-C 
goals with rosuvastatin compared with atorvastatin. 
These results support previous findings from pooled Phase III study data 
from 1182 patients with hypercholesterolemia in northern Europe and North 
America in the rosuvastatin clinical trials development program 19,32,33 and the 
DISCOVERY Triple Country study (1024 patients with hypercholesterolemia and
a high risk for CHD in Iceland, Ireland, and Finland), 34,35 in which significantly 
lower mean LDL-C levels were found and a significantly higher proportion of 
patients achieved European LDL-C goals with rosuvastatin 10 mg compared 
with atorvastatin 10 mg. Mean LDL-C reductions and the proportions of patients 
achieving 1998 and 2003 European LDL-C goals with rosuvastatin 10 mg were 
less in the present study than those observed in the rosuvastatin clinical trials 
development program 19,33 and the DISCOVERY Triple Country study. 34,35 This 
variability might reflect different populations studied. Nonetheless, these findings 
suggest that rosuvastatin ata starting dose of 10 mg is more effective compared 
with atorvastatin 10 mg in achieving LDL-C goals in clinical practice. 
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In the DISCOVERY Alpha study, increases in HDL-C levels were less than 
those observed in pooled data from the rosuvastatin clinical trials development 
program, 32 but were similar to those observed in another DISCOVERY study. 34 
Although it is unclear why increases in HDL-C were smaller in clinical practice 
compared with those in Phase III trials, the differences might be attributable to 
different methods or assays used at the various local laboratories in this study 
compared with those applied in the central aboratories of Phase III studies in 
the rosuvastatin clinical trials development program. 32 
The DISCOVERY Alpha study enrolled a large proportion of patients (-40%) 
who had not reached their goals with other LLTs. Although no formal statistical 
comparisons were performed, reductions in LDL-C levels were numerically 
smaller in individuals witched from other LLTs compared with LLT-naive pa- 
tients. This finding was expected because LDL-C levels had already been re- 
duced to some extent by the previous treatment. Nonetheless, rosuvastatin 
10 mg was associated with a 32.0% reduction in LDL-C levels in these individu- 
als, enabling more patients to achieve their lipid goals. 
The clinical benefits of LLT in the prevention of CVD, such as CHD and stroke, 
are well established. 13,36-39 In recent years, lipid goals have become more strin- 
gent. The ATP III guidelines 8 suggest that an even lower LDL-C goal of <70 mg/dL 
(1.8 mmol/L) can be applied to patients with established atherosclerotic dis- 
ease who are at very high risk for cardiovascular events. 1° The trend toward 
lower lipid goals is supported by data from the TNT study, 13 which reported 
that a reduction in mean LDL-C levels to 77 mg/dL (2 mmol/L) with atorvastatin 
80 mg was associated with a 22% relative risk reduction in major cardiovas- 
cular events, compared with a reduction in mean LDL-C levels to 101 mg/dL 
(2.6 mmol/L) with atorvastatin 10 mg. 13 The PRavastatin Or atorVastatin 
Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22 
(PROVE IT-TIMI 22) study 4° found that the reduction in median LDL-C level was 
greater with atorvastatin 80 mg compared with pravastatin 40 mg (median LDL-C 
levels, 1.60 mmol/L [62 mg/dL] vs 2.46 mmol/L [95 mg/dL]) (16% relative risk 
reduction in major cardiovascular outcomes; P < 0.005) in patients following an 
acute coronary syndrome. Furthermore, there were no safety concerns associ- 
ated with treating patients to achieve lower lipid levels in the PROVE IT-TIMI 22 
study. 41 In the present study, the rates of achievement of lipid goals with rosu- 
vastatin 10 mg and atorvastatin 10 mg were lower when the more stringent 2003 
guidelines were used compared with the 1998 guidelines. 
Because achieving lipid goals has been associated with improvements in 
cardiovascular outcomes, 11J2 rosuvastatin might be clinically beneficial. The po- 
tential for most patients to achieve lipid goals with a starting dose of an effica- 
cious LLT has the practical advantage of reducing the need for dose titration. 
Currently, many patients who would benefit from LLT are not managed 
appropriately, resulting in a widespread failure to attain recommended lipid 
goals. 16 The EUROpean Action on Secondary Prevention through Intervention 
to Reduce Events II (EUROASPIRE II) study 42 of risk factor management, which 
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was conducted in 5556 patients with CHD in 15 European countries, reported 
that only 51% achieved their treatment goal of TC <5.0 mmol/L (200 mg/dL) 
while receiving LLT. This finding can be partially explained by the observation 
that 64% of physicians choose the lowest dose of a statin and titrate the dose 
according to the lipid response in only 15% of patients. 17 Therefore, the use of 
statins that are effective at starting doses might help patients achieve LDL-C 
goals without dose titration. 
In the DISCOVERY Alpha study, both rosuvastatin 10 mg and atorvastatin 
10 mg were well tolerated, with similar profiles of AEs reported with the 2 agents. 
The numbers and types of AEs and serious AEs were consistent with the popu- 
lation and the agents tudied. In a review article, Rosenson 43 noted that statins 
have been associated with muscular AEs. However, in this study we found no 
reports of myopathy or rhabdomyolysis, and rates of myalgia were low and sim- 
ilar between the 2 treatment groups (rosuvastatin 0.6%; atorvastatin, 0.8%). 
These findings are consistent with data from a previous 12-week study of rosu- 
vastatin 10 mg and atorvastatin 10 mg in 519 patients with hypercholes- 
terolemia in North America, 24 in which the incidences of myalgia were 0.8% and 
3.9%, respectively. In general, studies over longer durations (-1 year) have indi- 
cated that the incidence of myalgia with atorvastatin or rosuvastatin is 
~3%. 25,44,45 This incidence is also similar to those observed with simvastatin and 
pravastatin. 46 
Although urinalysis was not performed in the present study, proteinuria was 
observed with statins in a previous study, 47 with an incidence slightly higher 
than that observed with placebo (0%-1.2% vs 0.6%). Statin-induced proteinuria 
appears to be transient, predominantly of tubular origin, 48 and has not been 
associated with reductions in renal function. 47 In keeping with these findings, 
only clinically nonsignificant changes in mean serum creatinine level, a marker 
of renal function, were observed in the present study. 
Higher statin doses have been associated with an increased incidence of 
clinically relevant elevations in hepatic aminotransferase levels. 49 Two trial 
analyses 44,49 have reported that the occurrence of persistent clinically relevant 
increases in hepatic aminotransferase levels with commonly available statins is 
low, typically <0.5% at the starting dose. This rate is in agreement with the in- 
cidence of clinically relevant increases in hepatic aminotransferase levels 
reported in the present study (0.1%-0.2%). Therefore, rosuvastatin appears to 
be similarly well tolerated to atorvastatin but, with its greater efficacy for 
reducing LDL-C, it provides a better benefit-to-risk ratio. 
Study Strengths and Weaknesses 
The patients in this study had primary hypercholesterolemia andhad an ele- 
vated risk for cardiovascular events. Therefore, they were generally representative 
of the population ormally considered for statin treatment in routine clinical prac- 
tice. In addition, this study extended the data on the efficacy of rosuvastatin to
populations in eastern Europe, Central and South America, and the Middle East. 
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Limitations of the current study include the subsequent recalculation of 
LDL-C levels from locally obtained ata for consistency using the Friedewald 
formula. 31 Thus, some patients with LDL-C levels outside the range specified in 
the inclusion criteria were included in the study (rosuvastatin, 48 [4.8%]; ator- 
vastatin, 28 [5.6%]). However, because patients were included based on locally 
determined ata, inclusion of these individuals would more accurately reflect 
local practice. Therefore, these patients were included in the ITT population. 
Furthermore, it is not expected that the use of the Friedewald formula 31 for con- 
sistency within the study instead of locally determined LDL-C levels affect- 
ed the percentage changes in lipid concentrations or the overall conclusions 
of the study. The other exclusion criteria used in this study reflected the 
contraindications in the prescribing information of these agents, 29 which is 
expected to reflect clinical practice. 
The size and duration of the study were sufficient to determine differences in
the primary efficacy end point but might have been inadequate to observe rare 
AEs, thus limiting any conclusions about tolerability. 
Within both treatment groups, mean compliance was >100% (rosuvastatin 
101.1%; atorvastatin 100.8%). This apparent "overcompliance" might have 
been the result of patients having lost tablets or not returning unused 
tablets. Failure to return unused tablets would increase the calculated 
amount of drug received, leading to a possible compliance rate of >100%. 
It is likely that the failure of patients to return unused tablets, rather than 
patients consistently having received >1 tablet/d, was the cause of this 
apparent overcompliance. Given that compliance data were poorly recorded, 
actual overcompliance annot be discounted. Nonetheless, poor recording 
of compliance reflects actual clinical practice and, because the apparent 
overcompliance occurred to a similar extent in both treatment groups, it is 
not expected that the analysis and interpretation of treatment effects was 
affected. 
The trial was not blinded. Although this limitation was not expected to 
have influenced lipid variables, it might have affected the reporting of AEs. 
For example, any speculation about the tolerability of an agent in the media 
or literature might have influenced whether a patient would report an AE to 
an investigator and whether an investigator would consider an AE to be treat- 
ment related. Furthermore, patients might have been more likely to report 
AEs with a new agent (rosuvastatin) than with an agent that is already estab- 
lished as being well tolerated (atorvastatin). Nonetheless, AE rates were sim- 
ilar between the 2 treatment groups and were in line with rates reported in 
previous blinded studies with rosuvastatin 10 mg and atorvastatin 10 mg, sug- 
gesting that the lack of blinding had little effect. 24,44 Furthermore, efficacy/ 
goal achievement rates in the present study were similar to those reported in 
the previous blinded, Phase III rosuvastatin clinical trials development pro- 
gram studies, 19,32,33 suggesting that, as expected, the lack of blinding had a 
minimal effect. 
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CONCLUSIONS 
In this study in patients with pr imary hypercholesterolemia and a high risk for 
CVD in clinical practice, greater eductions in LDL-C levels were achieved with 
a starting dose (10 mg) of rosuvastatin compared with atorvastat in 10 mg, with 
more of the former patients achieving European LDL-C goals. Both treatments 
were well tolerated. 
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Appendix. The DISCOVERY Alpha Study Investigators. 
The following physicians were investigators in the DISCOVERY Alpha study: 
Chile: Ada M. Cuevas, Hospital Universidad Catolica, Santiago; Carlos Grekin, 
Hospital Militar, Providencia, Santiago; Dominican Republic: Rafael Pichardo, 
Instituto Dominicano de Cardiologia, Santo Domingo; El Salvador: Juan Castro, 
Clinica Medica El Salvador, San Salvador; Hugo Villarroel, Plaza Villavicencio, 
Colonia Escal6n; Estonia: Arvo Mesikepp, East Tallinn Central Hospital, Tallinn; 
Jfiri Kaik, Estonian Institute of Cardiology, Tallinn; Jaan Eha and Margus 
Viigimaa, Tartu University Clinics, Tartu; Veiko Vahula, Parnu Hospital, Parnu; 
Guatemala: Franklin Hasse, Liga del Corazon, Guatemala City; Honduras: 
Alejandro Villena, Centro M~dico Hondureflo, Tegucigalpa; Rafael Ramirez, 
Hospital y Clinicas Viera, Tegucigalpa; Israel: Avishay Elis, A Meir Medical 
Center, Kfar-Saba, Tel Aviv; Shmuel Pasternak, Clalit Health Care Services, Tel 
Aviv; Agnes Muller, Clalit Health Care Services, Tel Aviv; Henia Brenner, Shaaria 
Clinic, Clalit Health Care Services, Petah-Tikva; Adiv Goldhaber, Clalit Health 
Care Services, Raanana; Vered Simovich, Clalit Health Care Services, Nes-Ziona; 
Irena Shapiro, Shafrir Clinic, Clalit Health Care Services, Kfar Habad; Horia 
Flandra, Wingate Clinik, Clalit Health Care Services, Beer-Sheva; Cilia Furman, 
New Dalet Clinik, Clalit Health Care Services, Beer-Sheva; Evgene Shveydel, 
Clalit Health Care Services, Sderot; Natalye Shveydel, Clalit Health Care Ser- 
vices, Kibbutz Mefalsim, Ashkelon Shore; Amnon Lahad, Shimshom Clinic, 
Clalit Health Care Services, Bet-Shemesh; Frida Glikberg, Neve Yaacov Clinic, 
Clalit Health Care Services, Jerusalem; Itzhak Baruch, Lin Clinic, Clalit Health 
Care Services, Haifa; Oscar R. Minuchin, Clalit Health Care Services, Zevulun 
Clinic, Kiriat-Bialic; Kuwait: Kochunny Menon and Abdulla Bin Nekhi, Amiri 
Hospital, Safat; Nasser Hayatt, Chest Hospital, Safat; Farida AI Habib, Defence 
Hospital, Safat; Mohammed Zubaid, Mubarak Hospital, Hawaii; Ghassan Baidas, 
Sabah Hospital, Safat; Amin Marafee, Adan Hospital, Safat; Adnan Asousi, Jahra 
Hospital, Kuwait; Habib Steita, Muwasat Hospital, Salmiya; Latvia: Janina 
Romanova, P. Stradins Clinical University Hospital, Riga; Silvija Hansone, First 
Clinical Hospital of Riga, Riga; Nadezda Rozkova, Clinical Hospital Gailezers, 
Riga; Irina Veze, Veselibas Centers, Riga; Veronika Ecina, Out Patient De- 
partment, Ministry of Internal Affairs, Riga; Keisa Maija, private practice, 
Valmiera; Arcils Gersamija, Daugavpils Regional Hospital, Daugavpils; 
Nicaragua: ]klvaro Morales, Hospital Militar, Managua; Panama: Daniel Pichell, 
Cardi61ogos Asociados-Centro M~dico Paitilla, Marbella; Ricardo Lyma, 
Fundaci6n Panamefm de Coraz6n-Consultorios Medicos Paitilla, Marbella; 
Romania: Mircea Cinteza, Spitalul Universitar Bucuresti, Clinica Medicala III, 
Bucharest; Maria Dorobantu, Spitalul Clinic de Urgenta, Clinica Medicala 
Bucharest, Bucharest; Ginghina Carmen and Cezar Macarie, Institutul de boli 
cardiovasculare "CC. Iliescu," Bucharest; Nicolae Hancu, Centrul Clinic de 
Diabet, Nutritie si Boli Metabolice, Cluj-Napoca; Stefan Dragulescu, Institutul de 
(continued) 
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boli cardiovasculare, Timisoara; Constantin Georgescu, Institutul de boll cardio- 
vasculare si transplant, Targu-Mures; Dumitru Zdrenghea, Spitalul Clinic de 
Recuperate, Cluj-Napoca; Dan-Dominic Ionescu, Centrul de Cardiologie Craiova, 
Craiova; George Georgescu, Spitalul Clinic "Parhon," Centrul de cardiologie, 
Iasi; Radu Capilneanu, Institutul inimii "Nicolae Stancioiu," Cluj-Napoca; 
Russia: Nikolai Grazianski, Atherosclerosis Research Centre, Moscow; Boris 
A. Sidorenko, President Medical Centre, Moscow; Valery V. Kukharchuk, 
Cardiology Research Center, Moscow; Natalia V. Perova, Institute of Preven- 
tive Medicine, Moscow; Jury A. Karpov and Mareev V. Juryevich, Cardiol- 
ogy Research Center, Moscow; Gennadiy I. Storojakov, "Zil" Factory Hospital, 
Moscow; Kabalava J. Davidova, Moscow City Hospital #64, Moscow; Olga 
Moryleva, GP Cardiology Clinic "Medicina," Moscow; Saudi Arabia: Jihad A. 
Alburaiki, King Faisal Specialist Hospital, Riyadh; Khalid A1 Nimry, Security 
Forces Hospital, Riyadh; Muayed AI-Zaibag, King Abdulaziz Cardiac Center, 
National Guard Health Affairs, Riyadh; Mohammad Arafa, King Saud University, 
Riyadh; Slovenia: Irena Keber, Klini~ni Center Ljubljana, Ljubljana; Matija Cevc 
and Alenka Ce~, Klini~ni Center Ljubljana, Ljubljana; Breda Kokalj Limbek, ZD 
Dom~ale-Zasebna Kardiolo~ka Ambulanta, Dom~ale; Boris Kraja~:i~:, ZD Novo 
Mesto, Novo Mesto; Vojko Kani~ and Metka Koren, Splo~na Bolni~nica Maribor, 
Maribor; Davorin Benko and Martin Tretjak, Splo~na Bolni~nica Slovenj Gradec, 
Slovenj Gradec; Julija Tepee, Bolni~nica dr. Jo~eta Potr(:a, Ptuj; Herbert 
Bernhardt, KardioloSka ambulanta, Nova Gorica; Iztok Gradecki and Janez 
TopliSek, Splo~na bolni~nica Novo mesto, Novo mesto; United Arab Emirates: 
Mohammad Motaweh, AI Baraha Hospital, Dubai; Sherif Bakir, AI Qassimi 
Hospital, Sharja; Bahloul Gurbana, AI Ain Hospital, A1 Ain; Wael Almahmeed, AI
Jazira Hospital, Abu Dhabi; Yassin Ibrahim, Central Hospital, Abu Dhabi; Azan S. 
Binbrek, Rashid Hospital, Dubai; Abdul Razzak Madani, New Dubai Hospital, 
Dubai; Khaldoun Taha, American Hospital, Dubai; Bashir AI Afandi, Tawam 
Hospital/Cardio, A1 Ain; Yousef A. Boobess, Tawam Hospital/Endo, AI Ain; 
Mohamed AI-Bur, GHQ, Abu Dhabi; Mahmoud Benbarka, SKMC, Abu Dhabi; 
Mohamed Saeed, AI Noor Hospital, Abu Dhabi; and Nabelyon Taha, AI Maktoom 
Hospital, Dubai. 
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